Provectus Biopharmaceuticals, Inc. (PVCT)
USD 0.1
(-3.01%)
USD 0.1
(-3.01%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 9.04 Million USD | 9.39% |
| 2022 | 8.26 Million USD | 7.34% |
| 2021 | 7.7 Million USD | -74.99% |
| 2020 | 30.79 Million USD | 20.54% |
| 2019 | 25.54 Million USD | 31.66% |
| 2018 | 19.4 Million USD | 44.22% |
| 2017 | 13.45 Million USD | 528.21% |
| 2016 | 2.14 Million USD | -48.05% |
| 2015 | 4.12 Million USD | 314.66% |
| 2014 | 994.28 Thousand USD | -92.57% |
| 2013 | 13.37 Million USD | 638.79% |
| 2012 | 1.81 Million USD | -45.62% |
| 2011 | 3.33 Million USD | -57.44% |
| 2010 | 7.82 Million USD | 846.06% |
| 2009 | 827.15 Thousand USD | 78.92% |
| 2008 | 462.29 Thousand USD | -47.45% |
| 2007 | 879.67 Thousand USD | 9.67% |
| 2006 | 802.11 Thousand USD | -72.64% |
| 2005 | 2.93 Million USD | 44.13% |
| 2004 | 2.03 Million USD | 13.9% |
| 2003 | 1.78 Million USD | 53.26% |
| 2002 | 1.16 Million USD | 31878.9% |
| 2001 | 3644.00 USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 8.36 Million USD | -1.87% |
| 2024 Q1 | 8.52 Million USD | -5.68% |
| 2023 FY | 9.04 Million USD | 9.39% |
| 2023 Q3 | 9.2 Million USD | 2.51% |
| 2023 Q2 | 8.98 Million USD | 3.0% |
| 2023 Q1 | 8.72 Million USD | 5.52% |
| 2023 Q4 | 9.04 Million USD | -1.81% |
| 2022 Q2 | 8.59 Million USD | 9.79% |
| 2022 FY | 8.26 Million USD | 7.34% |
| 2022 Q1 | 7.82 Million USD | 1.61% |
| 2022 Q4 | 8.26 Million USD | -7.22% |
| 2022 Q3 | 8.9 Million USD | 3.71% |
| 2021 Q1 | 32.38 Million USD | 5.17% |
| 2021 Q3 | 3.54 Million USD | 15.34% |
| 2021 FY | 7.7 Million USD | -74.99% |
| 2021 Q2 | 3.07 Million USD | -90.5% |
| 2021 Q4 | 7.7 Million USD | 116.98% |
| 2020 Q1 | 26.68 Million USD | 4.45% |
| 2020 FY | 30.79 Million USD | 20.54% |
| 2020 Q2 | 29.31 Million USD | 9.86% |
| 2020 Q3 | 30.05 Million USD | 2.54% |
| 2020 Q4 | 30.79 Million USD | 2.45% |
| 2019 Q4 | 25.54 Million USD | 5.78% |
| 2019 Q3 | 24.15 Million USD | 1.98% |
| 2019 FY | 25.54 Million USD | 31.66% |
| 2019 Q1 | 22.49 Million USD | 15.93% |
| 2019 Q2 | 23.68 Million USD | 5.28% |
| 2018 Q3 | 17.71 Million USD | 2.81% |
| 2018 FY | 19.4 Million USD | 44.22% |
| 2018 Q4 | 19.4 Million USD | 9.57% |
| 2018 Q1 | 15.55 Million USD | 15.6% |
| 2018 Q2 | 17.22 Million USD | 10.75% |
| 2017 Q2 | 9.14 Million USD | 68.38% |
| 2017 Q1 | 5.43 Million USD | 153.56% |
| 2017 Q3 | 11.16 Million USD | 22.05% |
| 2017 FY | 13.45 Million USD | 528.21% |
| 2017 Q4 | 13.45 Million USD | 20.56% |
| 2016 FY | 2.14 Million USD | -48.05% |
| 2016 Q4 | 2.14 Million USD | -60.16% |
| 2016 Q3 | 5.37 Million USD | 218.34% |
| 2016 Q1 | 1.83 Million USD | -55.5% |
| 2016 Q2 | 1.68 Million USD | -7.95% |
| 2015 Q2 | 995.44 Thousand USD | -7.4% |
| 2015 FY | 4.12 Million USD | 314.66% |
| 2015 Q4 | 4.12 Million USD | 98.73% |
| 2015 Q3 | 2.07 Million USD | 108.41% |
| 2015 Q1 | 1.07 Million USD | 8.12% |
| 2014 Q2 | 2.11 Million USD | -66.2% |
| 2014 FY | 994.28 Thousand USD | -92.57% |
| 2014 Q1 | 6.27 Million USD | -53.13% |
| 2014 Q4 | 994.28 Thousand USD | -52.84% |
| 2014 Q3 | 2.1 Million USD | -0.53% |
| 2013 FY | 13.37 Million USD | 638.79% |
| 2013 Q4 | 13.37 Million USD | 229.78% |
| 2013 Q3 | 4.05 Million USD | 34.07% |
| 2013 Q2 | 3.02 Million USD | -20.7% |
| 2013 Q1 | 3.81 Million USD | 110.7% |
| 2012 Q3 | 3.58 Million USD | -22.05% |
| 2012 FY | 1.81 Million USD | -45.62% |
| 2012 Q4 | 1.81 Million USD | -49.51% |
| 2012 Q1 | 4.25 Million USD | 27.84% |
| 2012 Q2 | 4.6 Million USD | 8.08% |
| 2011 Q2 | 5.69 Million USD | -46.37% |
| 2011 Q3 | 4.5 Million USD | -20.91% |
| 2011 FY | 3.33 Million USD | -57.44% |
| 2011 Q4 | 3.33 Million USD | -26.04% |
| 2011 Q1 | 10.61 Million USD | 35.63% |
| 2010 Q1 | 527.93 Thousand USD | -36.17% |
| 2010 FY | 7.82 Million USD | 846.06% |
| 2010 Q4 | 7.82 Million USD | 665.04% |
| 2010 Q3 | 1.02 Million USD | 30.69% |
| 2010 Q2 | 782.69 Thousand USD | 48.26% |
| 2009 Q1 | 650.33 Thousand USD | 40.68% |
| 2009 FY | 827.15 Thousand USD | 78.92% |
| 2009 Q4 | 827.15 Thousand USD | -0.8% |
| 2009 Q3 | 833.79 Thousand USD | -18.45% |
| 2009 Q2 | 1.02 Million USD | 57.22% |
| 2008 Q2 | 362.75 Thousand USD | 4.45% |
| 2008 FY | 462.29 Thousand USD | -47.45% |
| 2008 Q1 | 347.29 Thousand USD | -60.52% |
| 2008 Q4 | 462.29 Thousand USD | -30.65% |
| 2008 Q3 | 666.57 Thousand USD | 83.75% |
| 2007 Q4 | 879.67 Thousand USD | 20.34% |
| 2007 Q2 | 473.7 Thousand USD | 33.54% |
| 2007 Q1 | 354.72 Thousand USD | -55.78% |
| 2007 Q3 | 730.98 Thousand USD | 54.31% |
| 2007 FY | 879.67 Thousand USD | 9.67% |
| 2006 Q2 | 857.56 Thousand USD | -15.34% |
| 2006 Q1 | 1.01 Million USD | -65.45% |
| 2006 FY | 802.11 Thousand USD | -72.64% |
| 2006 Q4 | 802.11 Thousand USD | -9.95% |
| 2006 Q3 | 890.73 Thousand USD | 3.87% |
| 2005 Q3 | 2.4 Million USD | -3.44% |
| 2005 Q4 | 2.93 Million USD | 21.66% |
| 2005 FY | 2.93 Million USD | 44.13% |
| 2005 Q1 | 2.28 Million USD | 12.56% |
| 2005 Q2 | 2.49 Million USD | 9.0% |
| 2004 Q4 | 2.03 Million USD | 7.82% |
| 2004 Q3 | 1.88 Million USD | -9.95% |
| 2004 Q1 | 1.9 Million USD | 6.58% |
| 2004 Q2 | 2.09 Million USD | 10.06% |
| 2004 FY | 2.03 Million USD | 13.9% |
| 2003 FY | 1.78 Million USD | 53.26% |
| 2003 Q4 | 1.78 Million USD | -8.11% |
| 2003 Q3 | 1.94 Million USD | 41.04% |
| 2003 Q2 | 1.37 Million USD | 17.98% |
| 2003 Q1 | 1.16 Million USD | 0.23% |
| 2002 Q1 | 3644.00 USD | 0.0% |
| 2002 FY | 1.16 Million USD | 31878.9% |
| 2002 Q3 | 49.85 Thousand USD | 63.67% |
| 2002 Q2 | 30.45 Thousand USD | 735.84% |
| 2002 Q4 | 1.16 Million USD | 2237.59% |
| 2001 Q1 | - USD | 0.0% |
| 2001 FY | 3644.00 USD | 0.0% |
| 2001 Q4 | 3644.00 USD | 7.18% |
| 2001 Q3 | 3400.00 USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -32861.01% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 4.476% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 87.523% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -1017.985% |
| Rebus Holdings, Inc. | 5.24 Million USD | -72.495% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 84.678% |
| Qrons Inc. | 1.48 Million USD | -507.383% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -637.408% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 87.931% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -20130.432% |
| Skye Bioscience, Inc. | 14.07 Million USD | 35.744% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 83.037% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 5.634% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -2044.896% |
| SQZ Biotechnologies Company | 50.03 Million USD | 81.93% |
| Intellipharmaceutics International Inc. | 12 Million USD | 24.703% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -134.775% |
| Mesoblast Limited | 188.44 Million USD | 95.202% |
| Marizyme, Inc. | 26.67 Million USD | 66.103% |
| Genus plc | 485 Million USD | 98.136% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -54.763% |
| Pharming Group N.V. | 244.07 Million USD | 96.295% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -349.831% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -259.341% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -137.952% |
| ContraFect Corporation | 32.53 Million USD | 72.204% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -356.375% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -136.234% |
| IMV Inc. | 37.93 Million USD | 76.163% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 23.229% |
| MultiCell Technologies, Inc. | 1617.67 USD | -558864.066% |
| ONE Bio Corp. | 27.49 Million USD | 67.114% |
| Accustem Sciences Inc. | 1.07 Million USD | -737.831% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 88.32% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -327.513% |
| Q BioMed Inc. | 8.13 Million USD | -11.18% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 89.097% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -75.712% |
| Biomind Labs Inc. | 1.49 Million USD | -503.371% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 92.384% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 50.867% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -530.619% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -6263.485% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -4396.009% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -57.37% |
| GB Sciences, Inc. | 5.41 Million USD | -66.905% |
| Alpha Cognition Inc. | 7.16 Million USD | -26.203% |
| HST Global, Inc. | 593.59 Thousand USD | -1423.299% |
| CSL Limited | 18.62 Billion USD | 99.951% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -618.094% |
| Halberd Corporation | 728.71 Thousand USD | -1140.834% |
| Enzolytics Inc. | 365.26 Million USD | 97.525% |
| Agentix Corp. | 2.51 Million USD | -260.167% |
| Resverlogix Corp. | 67.39 Million USD | 86.583% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -978.079% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 97.968% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -427.549% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 63.46% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 24.035% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -146.706% |
| AVAX Technologies, Inc. | 3.99 Million USD | -126.409% |
| Zenith Capital Corp. | 27.56 Thousand USD | -32698.411% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.318% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -3688.83% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -142.139% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -1228.106% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -233.458% |
| Kadimastem Ltd | 3.5 Million USD | -157.99% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -13410.129% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 82.011% |
| BioStem Technologies, Inc. | 15.9 Million USD | 43.148% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1845.817% |
| LadRx Corporation | 2.2 Million USD | -310.91% |
| Cell Source, Inc. | 15.8 Million USD | 42.795% |
| Regen BioPharma, Inc. | 5.45 Million USD | -65.68% |
| Regen BioPharma, Inc. | 5.45 Million USD | -65.68% |
| NovAccess Global Inc. | 7.86 Million USD | -15.03% |
| Affymax, Inc. | 8.87 Million USD | -1.93% |
| Itoco Inc. | 1.65 Million USD | -446.967% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -340.746% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -49.482% |
| Mobile Lads Corp. | 1.31 Million USD | -588.406% |
| CytoDyn Inc. | 127.89 Million USD | 92.93% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -21532.561% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -477.268% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 18.135% |
| SYBLEU INC | 681.41 Thousand USD | -1226.977% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -48.186% |
| International Stem Cell Corporation | 5.27 Million USD | -71.351% |
| Bioxytran, Inc. | 3.24 Million USD | -178.264% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -1344.881% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -95.84% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 77.944% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 59.388% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -346.443% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -65.064% |
| Neutra Corp. | 973.52 Thousand USD | -828.806% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 68.836% |
| PureTech Health plc | 125.58 Million USD | 92.8% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -140.668% |
| IXICO plc | 1.9 Million USD | -375.832% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 55.954% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 91.249% |
| CSL Limited | 18.62 Billion USD | 99.951% |
| Cellectis S.A. | 249.36 Million USD | 96.374% |